New insider activity at Immunocore Holdings ( (IMCR) ) has taken place on March 20, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Baker Bros. Advisors Lp has made a significant investment in Immunocore Holdings by purchasing 807,338 shares of the company’s stock. This transaction is valued at an impressive $23,992,063, highlighting a strong vote of confidence in the company’s potential.
Recent Updates on IMCR stock
In the last 24 hours, Immunocore Holdings has been in the spotlight due to several key developments. The company announced promising initial data from its Phase 1/2 STRIVE trial for the HIV treatment candidate IMC-M113V, which showed dose-dependent viral control, potentially reducing the need for lifelong antiretroviral therapy. This announcement was made at the CROI 2025 conference and marks a significant advancement in HIV treatment. Additionally, Morgan Stanley assumed coverage of Immunocore with an Equal Weight rating, noting that while Kimmtrak sales are positive, they are already reflected in the stock price. Meanwhile, Oppenheimer lowered its price target for Immunocore, citing the company’s recent Q4 earnings report, which showed Kimmtrak revenues slightly exceeded expectations. The firm anticipates 2025 to be a year of execution for Immunocore’s clinical pipeline, with limited updates expected, except for the forthcoming Phase 1 data on the HIV candidate IMCM113V.
More about Immunocore Holdings
YTD Price Performance: -4.85%
Average Trading Volume: 279,131
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.42B